Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
TNYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.39 - $4.96
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.34M
Market Cap
$82.49M
Enterprise Value$101.36M
Total Cash (Recent Filing)$4.32M
Total Debt (Recent Filing)$13.61M
Price to Earnings (P/E)―
Beta2.95
Next Earnings
May 07, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding162,582,640
10 Day Avg. Volume2,559,427
30 Day Avg. Volume4,340,382
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$10.14Price Target Upside2104.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Clinical DataUpdated Ph1b/2a data for TN-201 showed additional signs of potential activity and a tolerable safety profile in a severe HCM patient population.
Safety ProfileTN-401's emerging safety profile remains consistent with comparable AAV gene therapies and known immunosuppressive regimens.
Bears Say
Financial StabilityTenaya Therapeutics has approximately 1.5 years of cash left, indicating a potential need for future financing.
Market SentimentTenaya’s short interest stands at 8.1% of float, which could imply significant bearish sentiment towards the stock.
---
Ownership Overview
72.98% Insiders
6.00% Mutual Funds
0.03% Other Institutional Investors
17.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.39 and its highest was $4.96 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $82.49M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 19 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Mar 10, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.311 by $0.031.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 162,582,640 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.311. Following the earnings report the stock price went up 8%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
---
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.14 (2104.35% Upside)
$10.14 (2104.35% Upside)
Hedge Fund Trend
Decreased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.66%
12-Months-Change
Fundamentals
Return on Equity
-95.69%
Trailing 12-Months
Asset Growth
-27.67%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
---
TNYA Stock 12 Month Forecast
Average Price Target
$10.14
▲(2104.35% Upside)
Technical Analysis
Veru
―
Black Diamond Therapeutics
―
Pliant Therapeutics
―
Elicio Therapeutics
―
Telomir Pharmaceuticals, Inc.
―
Best Analysts Covering TNYA
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-41.53%
reiterated a buy rating 26 days ago
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -41.53% per trade.
---